HIV seroconverting donors delay their return: Screening test implications

Transfusion

Volumn 42, Issue 4, 2002, Pages 414-421

  Schreiber, George B ^a,b,c   Glynn, Simone A ^a,b,c   Satten, Glen A ^a,b,c   Kong, Fanhui ^a,b,c   Wright, David ^a,b,c   Busch, Michael P ^a,b,c   Tu, Yongling ^a,b,c   Kleinman, Steven H ^a,b,c  

^a WESTAT   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Blood Centers of the Pacific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HUMAN T CELL LEUKEMIA VIRUS ANTIBODY;

ARTICLE; BLOOD; BLOOD DONOR; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; RISK FACTOR; SEXUAL BEHAVIOR; TIME; VIROLOGY;

BLOOD DONORS; DELTARETROVIRUS ANTIBODIES; HEPACIVIRUS; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV CORE PROTEIN P24; HIV SEROPOSITIVITY; HUMANS; RISK FACTORS; SEXUAL BEHAVIOR; TIME FACTORS;

EID: 0036528260     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2002.00084.x     Document Type: Article

References (25)

1. 1 Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type I seroconversion: implications for screening of blood and tissue donors. Transfusion 1995 ; 35: 91 ‐ 7.
2. 2 Busch MP, Stramer SL. The efficiency of HIV p24 antigen screening of US blood donors: projections versus reality. Infusionsther Transfusions med 1998 ; 25: 5 ‐ 8.
3. 3 Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000;40:1165‐8.
4. 4 Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion‐transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997 ; 11: 155 ‐ 72.
5. 5 Kleinman SH, Busch MP. The risks of transfusion‐transmitted infection: direct estimation and mathematical modelling. Baillieres Clin Haematol 2000 ; 13: 631 ‐ 49.
6. 6 Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988 ; 148: 945 ‐ 9.
7. 7 Vanhems P, Beaulieu R. Primary infection by type 1 human immunodeficiency virus: diagnosis and prognosis. Postgrad Med J 1997 ; 73: 403 ‐ 8.
8. 8 Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in human and animal retrovirus infections. J Infect Dis 1993 ; 168: 1490 ‐ 501.
9. 9 Moyer LA, Mast EE. Hepatitis B: Virology, epidemiology, disease and prevention, and an overview of viral hepatitis. Am J Prev Med 1994 ; 10 (Suppl): 45 ‐ 55.
10. 10 Barker LF, Murray R. Acquisition of hepatitis‐associated antigen: clinical features in young adults. JAMA 1971 ; 216: 1970 ‐ 6.
11. 11 Bennett JC, Plum F, eds. Cecils textbook of medicine, 20th ed. Philadelphia: W.B. Saunders, 1996.
12. 12 Shapiro CN. Epidemiology of hepatitis B. Pediatr Infect Dis J 1993 ; 12: 433 ‐ 7.
13. 13 Lee WM, Hepatitis B virus infection. N Engl J Med 1997;337:1733‐45.
14. 14 Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV‐related chronic disease. Centers for Disease Control and Prevention. MMWR Morbid Mortal Wkly Rpt 1998;47(RR‐19):1‐39.
15. 15 Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999 ; 107: 2S–9S.
16. 16 Hollsberg P, Hafler DA. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N Engl J Med 1993 ; 328: 1173 ‐ 82.
17. 17 Murphy EL, Glynn SA, Fridey J, et al. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I‐ and II‐infected blood donors. J Infect Dis 1997 ; 176: 1468 ‐ 75.
18. 18 Zuck TF, Thomson RA, Schreiber GB, et al. The Retrovirus Epidemiology Donor Study (REDS): rationale and methods. Transfusion 1995 ; 35: 994 ‐ 51.
19. 19 Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion‐transmissible viral infections in US blood donors, 1991‐1996. JAMA 2000 ; 284: 229 ‐ 35.
20. 20 Cox DR. Renewal theory. London: Methuen, 1962.
21. 21 Satten GA. Steady‐state calculation of the risk of HIV infection from transfusion of screened blood from repeat donors. Math Biosci 1997 ; 141: 101 ‐ 13.
22. 22 Cable RG, Aberle‐Grasse J, Layug L, Williams AE. HIV infected blood donors have a long interdonation interval: implications for HIV risk assessment (abstract). Transfusion 1997 ; 37 (Suppl): 109S.
23. 23 Glynn SA, Kleinman SH, Schreiber GB, et al. Motivations to donate blood: demographic comparisons. Transfusion 2002 ; 42: 216 ‐ 25.
24. 24 Korelitz JJ, Busch MP, Kleinman SH, et al. A method for estimating hepatitis B virus incidence rates in volunteer blood donors. Transfusion 1997 ; 37: 634 ‐ 40.
25. 25 Busch MP, Kleinman SA, Jackson B, et al. Nucleic acid amplification testing of blood donors for transfusion‐transmitted infectious diseases. Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 2000 ; 40: 143 ‐ 59.